VJHemOnc is committed to improving our service to you

SOHO 2020 | Venetoclax and ibrutinib based approaches in CLL

VJHemOnc is committed to improving our service to you

William Wierda

William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, explores venetoclax and ibrutinib based approaches in chronic lymphocytic leukemia (CLL). Specifically discussed is fixed-duration therapy with targeted agents as well as maintaining disease control using BTK inhibitors such as ibrutinib which, in contrast with venetoclax, which can provide deep remissions in some CLL patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter